Celldex Therapeutics, Inc.
No SEC Form 4 filings for $CLDX in the last 30 days.
Celldex Therapeutics (CLDX) reported Q2 adjusted EPS loss of $0.94 per share, better than the Zacks Consensus Estimate of a $1.04 loss. Revenue was $0.02 million, far below the consensus estimate, down from $0.73 million a year earlier. The article cites a Zacks Rank #2 (Buy) and upcoming consensus outlook of -$1.07 EPS on $1.86 million revenue for the next quarter.
Celldex Therapeutics, Inc. (CLDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Celldex Reports Second Quarter Financial Results and Provides Corporate Update Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submis
Celldex Therapeutics (CLDX) shares rose about 7.9% after the company reported topline Phase 2 results for prurigo nodularis in July 2026. The update is framed as supporting its dermatology pipeline and could affect expectations for future programs, with the next major catalyst cited as late-2026 Phase 3 EMBARQ-CSU.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CLDX (Celldex Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CLDX coverage spans earnings, sector analysis and financial news.
The print is a mixed earnings signal: EPS beat but extreme revenue miss, leaving near-term direction dependent on management commentary and updated estimate revisions.
The filing adds concrete clinical and regulatory timing signals (Phase 3 topline in Sept/Oct 2026, BLA planned for 2027) plus a Phase 2 discontinuation in prurigo nodularis.
Positive Phase 2 readout can broaden the dermatology thesis, but the text provides no efficacy/safety numbers, so near-term trading is more sentiment than new fundamentals.
Discontinuation reduces near-term clinical optionality for barzolvolimab in prurigo nodularis, pressuring pipeline value for that indication.
The article frames the Phase 2 readout as reinforcing Celldex’s dermatology investment case, while treating the CFO transition as continuity rather than a thesis change.
alphai scores every news story that mentions CLDX with an AI model for sentiment and relevance, and aggregates insider trades from Celldex Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Celldex Therapeutics (CLDX) reported Q2 adjusted EPS loss of $0.94 per share, better than the Zacks Consensus Estimate of a $1.04 loss. Revenue was $0.02 million, far below the consensus estimate, down from $0.73 million a year earlier. The article cites a Zacks Rank #2 (Buy) and upcoming consensus outlook of -$1.07 EPS on $1.86 million revenue for the next quarter.
2 min readCelldex Therapeutics, Inc. (CLDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Celldex Reports Second Quarter Financial Results and Provides Corporate Update Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submis
6 min readCelldex Therapeutics (CLDX) shares rose about 7.9% after the company reported topline Phase 2 results for prurigo nodularis in July 2026. The update is framed as supporting its dermatology pipeline and could affect expectations for future programs, with the next major catalyst cited as late-2026 Phase 3 EMBARQ-CSU.
6 min readThe article reviews pharma news. Halozyme Therapeutics said it signed a licensing deal with Incyte for INCA033989. Samsung Biologics plans to buy Swiss firm PolyPeptide for about $1.8 billion. Celldex reported mixed barzolvolimab results in prurigo nodularis and will stop that program. Sanofi will discontinue amlitelimab development in atopic dermatitis.
6 min readSimply Wall St discusses Celldex Therapeutics (CLDX) after it reported Phase 2 topline results for prurigo nodularis and announced CFO Sam Martin will retire around March 31, 2027. The piece links the data to barzolvolimab’s dermatology potential and notes valuation and funding risks amid ongoing losses and equity raises.
6 min readBiotech weekly roundup highlights EU approval for AstraZeneca’s Etcamah plus CDK4/6 inhibitors in ESR1-mutant ER+/HER2- advanced breast cancer, and accelerated FDA approval for GSK’s Jideytro in ROS1+ NSCLC. J&J received FDA De Novo for OTTAVA and reported Phase 3 PFS/OS gains for Talvey combos. Other items include deals (RGEN-BioLife, RPRX royalty buy) and trial updates for LLY, CLDX, and others.
7 min readCelldex Therapeutics said its 24-week, double-blind, placebo-controlled prurigo nodularis trial of barzolvolimab (140 patients) failed to meet the primary 12-week itch improvement endpoint and key secondary lesion outcomes. Mast cell depletion via reduced tryptase occurred, but symptoms did not improve. Celldex also previously halted EoE development. CLDX shares were down 6.06% premarket at $33.50.
3 min readCelldex said its subcutaneous monoclonal antibody barzolvolimab failed in a Phase II randomized, double-blind, placebo-controlled trial in prurigo nodularis (NCT06366750). Patients did not achieve significant improvement on the WI-NRS at week 12 versus placebo, and key secondary endpoints also missed. Celldex is discontinuing the PN Phase II study; stock was expected to fall at the open.
6 min readCelldex (CLDX) reported topline Phase 2 results for barzolvolimab in prurigo nodularis, saying the study did not meet the primary WI-NRS Week 12 endpoint or key secondary endpoints at either dose. Celldex will discontinue the PN Phase 2 trial and cited prior safety/tolerability. CLDX fell in after-hours.
4 min readAfter-hours movers: Super Micro Computer (SMCI) rose ~20% on a bullish preliminary Q4 FY2026 update, with gross margins at 15% to 17% and new orders above $60B. Oklo (OKLO) and X-Energy (XE) gained on reports of a $200M federal program for nuclear power for AI data centers. Pegasystems (PEGA) fell on Q2 EPS and revenue misses. Celldex (CLDX) dropped after a Phase 2 trial failed endpoints. Alaska Air Group (ALK) slid on a weaker Q3 outlook.
4 min read
